Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - Oct 24, 2025 - P1 | N=28 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: May 2025 ➔ Dec 2025 | Trial primary completion date: May 2025 ➔ Dec 2025
Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor
|